Assessing potential of psilocybin for depressive disorders

References

• Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317(15):1517. doi: 10.1001/jama.2017.3826
   Web of Science ®Google Scholar
• World Health Organization. Depression and other common mental disorders: global health estimates [Internet]. World Health Organization; 2017 [cited 2023 Jul 14]. Report No.: WHO/MSD/MER/2017.2. Available from: https://apps.who.int/iris/handle/10665/254610.
   Google Scholar
• Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM-5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75(4):336–346. doi: 10.1001/jamapsychiatry.2017.4602
   PubMed Web of Science ®Google Scholar
• Brown S, Rittenbach K, Cheung S, et al. Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews. Can J Psychiatry. 2019;64(6):380–387. doi: 10.1177/0706743719828965
   PubMed Web of Science ®Google Scholar
• Johnston KM, Powell LC, Anderson IM, et al. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. J Affective Disorders. 2019;242:195–210. doi: 10.1016/j.jad.2018.06.045
   PubMed Web of Science ®Google Scholar
• Fekadu A, Wooderson SC, Markopoulo K, et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116(1–2):4–11. doi: 10.1016/j.jad.2008.10.014
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. AJP. 2006;163(11):1905–1917. doi: 10.1176/ajp.2006.163.11.1905
   Web of Science ®Google Scholar
• Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63(11):963–971. doi: 10.4088/JCP.v63n1102
   PubMed Web of Science ®Google Scholar
• Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry. 2004;65(3):341–347. doi: 10.4088/JCP.v65n0309
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181–1197. doi: 10.1177/0269881116675513
   PubMed Web of Science ®Google Scholar
• Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619–627. doi: 10.1016/S2215-0366(16)30065-7
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Aaronson ST, Alvarez O, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387(18):1637–1648. doi: 10.1056/NEJMoa2206443
   PubMed Web of Science ®Google Scholar
• Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489. doi: 10.1001/jamapsychiatry.2020.3285
   PubMed Web of Science ®Google Scholar
• Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384(15):1402–1411. doi: 10.1056/NEJMoa2032994
   PubMed Web of Science ®Google Scholar
• COMPASS Pathways. A phase III, multicentre, randomised, Double Blind, placebo-controlled study to investigate the efficacy, safety, and tolerability of a single administration of COMP360 in participants with treatment-resistant depression [Internet]. clinicaltrials.gov; [cited 2023 May 22]. Report No.: NCT05624268. Available from: https://clinicaltrials.gov/ct2/show/NCT05624268.
   Google Scholar
• Passie T, Seifert J, Schneider U, et al. The pharmacology of psilocybin. Addict Biol. 2002;7(4):357–364. doi: 10.1080/1355621021000005937
   PubMed Web of Science ®Google Scholar
• Hakami Zanjani AA, Nguyen TQT, Jacobsen L, et al. The molecular basis of the antidepressant action of the magic mushroom extract, psilocin. Biochim Biophys Acta Proteins Proteom. 2023;1871(4):140914. doi: 10.1016/j.bbapap.2023.140914
   PubMed Web of Science ®Google Scholar
• Madsen MK, Fisher PM, Burmester D, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacol. 2019;44(7):1328–1334. doi: 10.1038/s41386-019-0324-9
   PubMed Web of Science ®Google Scholar
• Béïque J-C, Imad M, Mladenovic L, et al. Mechanism of the 5-hydroxytryptamine 2A receptor-mediated facilitation of synaptic activity in prefrontal cortex. Proc Natl Acad Sci, USA. 2007;104(23):9870–9875. doi: 10.1073/pnas.0700436104
   PubMed Web of Science ®Google Scholar
• Johnson MW, Hendricks PS, Barrett FS, et al. Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacol Ther. 2019;197:83–102. doi: 10.1016/j.pharmthera.2018.11.010
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Richards WA, McCann U, et al. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. 2006;187(3):268–283. doi: 10.1007/s00213-006-0457-5
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacol (Berl). 2011;218(4):649–665. doi: 10.1007/s00213-011-2358-5
   PubMed Web of Science ®Google Scholar
• Moliner R, Girych M, Brunello CA, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26(6):1032–1041. doi: 10.1038/s41593-023-01316-5
   PubMed Web of Science ®Google Scholar
• Ly C, Greb AC, Cameron LP, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23(11):3170–3182. doi: 10.1016/j.celrep.2018.05.022
   PubMed Web of Science ®Google Scholar
• McClure-Begley TD, Roth BL. The promises and perils of psychedelic pharmacology for psychiatry. Nat Rev Drug Discov. 2022;21(6):463–473. doi: 10.1038/s41573-022-00421-7
   PubMed Web of Science ®Google Scholar
• Wacker D, Wang S, McCorvy JD, et al. Crystal structure of an LSD-Bound human serotonin receptor. Cell. 2017;168(3):377–389.e12. doi: 10.1016/j.cell.2016.12.033
   PubMed Web of Science ®Google Scholar
• Rodriguiz RM, Nadkarni V, Means CR, et al. LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1. Sci Rep. 2021;11(1):17690. doi: 10.1038/s41598-021-96736-3
   PubMed Web of Science ®Google Scholar
• Agin-Liebes G, Ekman E, Anderson B, et al. Participant reports of mindfulness, posttraumatic growth, and social connectedness in psilocybin-assisted group therapy: an interpretive phenomenological analysis. J Humanistic Psychol. 2021;00221678211022949.
   Web of Science ®Google Scholar
• Swift TC, Belser AB, Agin-Liebes G, et al. Cancer at the dinner table: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. J Humanistic Psychol. 2017;57(5):488–519. doi: 10.1177/0022167817715966
   Web of Science ®Google Scholar
• Watts R, Day C, Krzanowski J, et al. Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J Humanistic Psychol. 2017;57(5):520–564. doi: 10.1177/0022167817709585
   Web of Science ®Google Scholar
• Noorani T, Garcia-Romeu A, Swift TC, et al. Psychedelic therapy for smoking cessation: qualitative analysis of participant accounts. J Psychopharmacol. 2018;32(7):756–769. doi: 10.1177/0269881118780612
   PubMed Web of Science ®Google Scholar
• Griffith JW, Zinbarg RE, Craske MG, et al. Neuroticism as a common dimension in the internalizing disorders. Psychol Med. 2010;40(7):1125–1136. doi: 10.1017/S0033291709991449
   PubMed Web of Science ®Google Scholar
• Erritzoe D, Roseman L, Nour MM, et al. Effects of psilocybin therapy on personality structure. Acta Psychiatr Scand. 2018;138(5):368–378. doi: 10.1111/acps.12904
   PubMed Web of Science ®Google Scholar
• Weiss B, Ginige I, Shannon L, et al. Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression. Psychol Med. 2023;1–15.
   Web of Science ®Google Scholar
• Costa PT Jr., RR M. Neo personality Inventory. In: Kazdin AE, editor. Encyclopedia of psychology. Vol. 5. (WA) DC US: American Psychological Association; 2000. p. 407–409.
   Google Scholar
• Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abuse Rev. 2014;7(3):157–164. doi: 10.2174/1874473708666150107121331
   PubMedGoogle Scholar
• Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165–1180. doi: 10.1177/0269881116675512
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Forcehimes AA, Pommy JA, et al. Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol. 2015;29(3):289–299. doi: 10.1177/0269881114565144
   PubMed Web of Science ®Google Scholar
• Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse. 2017;43(1):55–60. doi: 10.3109/00952990.2016.1170135
   PubMed Web of Science ®Google Scholar
• Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. [cited 2023 May 20] 2018;8. InternetAvailable from. 10.3389/fphar.2017.00974
   PubMed Web of Science ®Google Scholar
• Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up. J Psychopharmacol. 2022;36(2):151–158. doi: 10.1177/02698811211073759
   PubMed Web of Science ®Google Scholar
• Sloshower J, Skosnik PD, Safi-Aghdam H, et al. Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial. J Psychopharmacol. 2023;37(7):698–706. doi: 10.1177/02698811231154852
   PubMed Web of Science ®Google Scholar
• Olson DE. The subjective effects of psychedelics May not be necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4(2):563–567. doi: 10.1021/acsptsci.0c00192
   PubMedGoogle Scholar
• Hesselgrave N, Troppoli TA, Wulff AB, et al. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci, USA. 2021;118(17):e2022489118. doi: 10.1073/pnas.2022489118
   PubMed Web of Science ®Google Scholar
• Rosenblat JD, Leon-Carlyle M, Ali S, et al. Antidepressant effects of psilocybin in the absence of psychedelic effects. AJP. 2023;180(5):395–396. doi: 10.1176/appi.ajp.20220835
   Google Scholar
• Goodwin GM, Malievskaia E, Fonzo GA, et al. Must psilocybin always “assist psychotherapy”? AJP. 2023. appi.ajp.20221043. doi: 10.1176/appi.ajp.20221043.
   PubMedGoogle Scholar
• von Rotz R, Schindowski EM, Jungwirth J, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. eClinicalmedicine. 2023;56:101809. doi: 10.1016/j.eclinm.2022.101809
   PubMedGoogle Scholar
• Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155–166. doi: 10.1177/0269881119897615
   PubMed Web of Science ®Google Scholar
• Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71–78. doi: 10.1001/archgenpsychiatry.2010.116
   PubMed Web of Science ®Google Scholar
• Agrawal M, Emanuel E, Richards B, et al. Assessment of psilocybin therapy for patients with cancer and major depression disorder. JAMA Oncol [Internet]. 2023 [cited 2023 Jun 5]; Available from: https://jamanetwork.com/journals/jamaoncology/fullarticle/2803623.
   Google Scholar
• Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. 2018;235(2):399–408. doi: 10.1007/s00213-017-4771-x
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Croal M, Feifel D, et al. Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacol. 2023;1–8.
   PubMed Web of Science ®Google Scholar
• Zeifman RJ, Singhal N, Breslow L, et al. On the relationship between classic psychedelics and suicidality: a systematic review. ACS Pharmacol Transl Sci. 2021;4(2):436–451. doi: 10.1021/acsptsci.1c00024
   PubMedGoogle Scholar
• Munafò A, Arillotta D, Mannaioni G, et al. Psilocybin for depression: from credibility to feasibility, What’s missing? Pharmaceuticals. 2023;16(1):68. doi: 10.3390/ph16010068
   Web of Science ®Google Scholar
• Cunningham JA, Kypri K, McCambridge J. Exploratory randomized controlled trial evaluating the impact of a waiting list control design. BMC Med Res Methodol. 2013;13(1):150. doi: 10.1186/1471-2288-13-150
   PubMedGoogle Scholar
• Dong C, Ly C, Dunlap LE, et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell. 2021;184(10):2779–2792.e18. doi: 10.1016/j.cell.2021.03.043
   PubMed Web of Science ®Google Scholar
• Husain MI, Blumberger DM, Castle DJ, et al. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych Open. 2023;9(4):e134. doi: 10.1192/bjo.2023.535
   PubMed Web of Science ®Google Scholar
• Davis AK, Levin AW, Nagib PB, et al. Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ Open. 2023;13(5):e068884. doi: 10.1136/bmjopen-2022-068884
   PubMed Web of Science ®Google Scholar
• Nayak S, Johnson MW. Psychedelics and psychotherapy. Pharmacopsychiatry. 2021;54(4):167–175. doi: 10.1055/a-1312-7297
   PubMedGoogle Scholar
• Wolff M, Evens R, Mertens LJ, et al. Learning to let go: a cognitive-behavioral model of how psychedelic therapy promotes acceptance. Front Psychiatry. 2020;11:5. doi: 10.3389/fpsyt.2020.00005
   PubMed Web of Science ®Google Scholar
• Yaden DB, Earp D, Graziosi M, et al. Psychedelics and psychotherapy: cognitive-behavioral approaches as default. Frontiers In Psychology. 2022;13:873279. doi: 10.3389/fpsyg.2022.873279
   PubMed Web of Science ®Google Scholar
• Yamauchi M, Miyara T, Matsushima T, et al. Desensitization of 5-HT2A receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Res. 2006;1067(1):164–169. doi: 10.1016/j.brainres.2005.10.075
   PubMed Web of Science ®Google Scholar
• Sanders-Bush E, Breeding M, Knoth K, et al. Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system. Psychopharmacol (Berl). 1989;99(1):64–69. doi: 10.1007/BF00634454
   PubMed Web of Science ®Google Scholar
• Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. Brain Res Bull. 2001;56(5):441–451. doi: 10.1016/S0361-9230(01)00623-2
   PubMed Web of Science ®Google Scholar
• Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacol. 1996;14(6):425–436. doi: 10.1016/0893-133X(95)00145-4
   PubMed Web of Science ®Google Scholar
• Nayak SM, Bradley MK, Kleykamp BA, et al. Control conditions in randomized trials of psychedelics: an ACTTION systematic review. J Clin Psychiatry. 2023;84(3):22r14518. doi: 10.4088/JCP.22r14518
   PubMed Web of Science ®Google Scholar
• Johansen P-Ø, Krebs TS. Psychedelics not linked to mental health problems or suicidal behavior: a population study. J Psychopharmacol. 2015;29(3):270–279. doi: 10.1177/0269881114568039
   PubMed Web of Science ®Google Scholar
• Hendricks PS, Thorne CB, Clark CB, et al. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29(3):280–288. doi: 10.1177/0269881114565653
   PubMed Web of Science ®Google Scholar
• Carbonaro TM, Bradstreet MP, Barrett FS, et al. Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences. J Psychopharmacol. 2016;30(12):1268–1278. doi: 10.1177/0269881116662634
   PubMed Web of Science ®Google Scholar
• Davis AK, Clifton JM, Weaver EG, et al. Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: phenomenology, interpretation, and enduring effects. J Psychopharmacol. 2020;34(9):1008–1020. doi: 10.1177/0269881120916143
   PubMed Web of Science ®Google Scholar
• Griffiths RR, Hurwitz ES, Davis AK, et al. Survey of subjective “god encounter experiences”: comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS One. 2019;14:e0214377. doi: 10.1371/journal.pone.0214377
   PubMed Web of Science ®Google Scholar
• Letheby C. Philosophy of psychedelics. Oxford (NY): Oxford University Press; 2021.
   Google Scholar
• Sjoberg BM, Hollister LE. The effects of psychotomimetic drugs on primary suggestibility. Psychopharmacologia. 1965;8(4):251–262. doi: 10.1007/BF00407857
   PubMed Web of Science ®Google Scholar
• Middlefell R. The effects of LSD on body sway suggestibility in a group of hospital patients. Br J Psychiatry. 1967;113(496):277–280. doi: 10.1192/bjp.113.496.277
   PubMed Web of Science ®Google Scholar
• Johnson MW. Consciousness, religion, and gurus: pitfalls of psychedelic Medicine. ACS Pharmacol Transl Sci. 2021;4(2):578–581. doi: 10.1021/acsptsci.0c00198
   PubMedGoogle Scholar
• Gioscia V. LSD subcultures: acidoxy versus orthodoxy. Am J Orthopsychiatry. 1969;39(3):428–436. doi: 10.1111/j.1939-0025.1969.tb00638.x
   PubMed Web of Science ®Google Scholar
• Paglia C. Cults and cosmic consciousness: religious vision in the American. Arion. 2003;10(3): 1–111.
   Google Scholar
• Aday JS, Heifets BD, Pratscher SD, et al. Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacol (Berl). 2022;239(6):1989–2010. doi: 10.1007/s00213-022-06123-7
   PubMed Web of Science ®Google Scholar